NOVUS THERAPEUTICS INC's ticker is NVUS and the CUSIP is 67011N105. A total of 18 filers reported holding NOVUS THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $421,000 | -78.8% | 90,199 | -68.2% | 0.26% | -62.9% |
| Q2 2018 | $1,984,000 | +16.2% | 283,383 | -16.4% | 0.71% | +28.4% |
| Q1 2018 | $1,708,000 | +24.1% | 338,929 | 0.0% | 0.55% | +19.8% |
| Q4 2017 | $1,376,000 | +57.6% | 338,929 | +102.3% | 0.46% | +36.2% |
| Q3 2017 | $873,000 | +266.8% | 167,577 | +311.1% | 0.34% | +251.0% |
| Q2 2017 | $238,000 | – | 40,766 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 3,183,314 | $54,435,000 | 0.68% |
| Asymmetry Capital Management, L.P. | 1,088,907 | $1,034,000 | 0.66% |
| BVF INC/IL | 3,515,873 | $3,340,000 | 0.18% |
| Renaissance Technologies | 758,149 | $720,000 | 0.00% |
| ACADIAN ASSET MANAGEMENT LLC | 170,176 | $162,000 | 0.00% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 20,282 | $19,000 | 0.00% |
| RAYMOND JAMES & ASSOCIATES | 11,000 | $10,000 | 0.00% |
| ROYAL BANK OF CANADA | 1 | $0 | 0.00% |
| UBS Group AG | 4,200 | $4,000 | 0.00% |
| THRIVENT FINANCIAL FOR LUTHERANS | 45,761 | $43,000 | 0.00% |